Eye cancer occurs when healthy cells in or around the eye change and grow uncontrollably leading to the formation of tumors. Different types of eye cancers are observed namely intraocular cancer, squamous cell cancer, rhabdomyosarcoma, and others. These types of cancer affects eyeball, orbit (eye socket), and adnexal (accessory) structures. Over 100 types of cancers have been identified. According to cancer research UK, in 2012, globally over 14.1 million of new cancer cases were registered, which is expected to increase continuously in coming future. Additionally, as per the report published in American Society of Clinical Oncology, in 2015, over 3500 patients in the US were diagnosed with primary intraocular cancer. Because of deteriorating lifestyle due to alcoholism and smoking, there is a continued rise in the incidence of cancer. The eye cancer market is majorly driven by the increasing prevalence of eye cancer across the globe. Additionally, increasing government support for research & development, rising healthcare expenditure and changing lifestyle has fuelled the market growth. Many types of treatment are available in the market, however, all the treatment show some or other side effects on the body. Side effects of the treatment, and high cost of the medicines may slow the growth of the market during the forecasted period.
The eye cancer market is expected to grow at a CAGR of ~8.3 % during the forecast period 2017-2023.
Figure 1- Market Synopsis of Eye Cancer Market Research, by Treatment 2016 (%)
Sources- WHO, cancer research UK, American Cancer Society
The eye cancer market is segmented on the basis of types, treatment and end users.
On the basis of types, the eye cancer market is segmented into intraocular cancer, squamous cell cancer, rhabdomyosarcoma, and others. Intraocular cancer is further segmented into melanoma of the eye, lymphoma of the eye, and eye cancers in children.
On the basis of treatment, the eye cancer market is categorised into chemotherapy, surgery & radiation therapy, targeted therapy, hormone therapy, biologic therapy, and other. Chemotherapy is further segmented into anthracyclines, taxanes, antimetabolites, and alkylating agents. Target therapy is sub segmented into monoclonal antibodies and tyrosine kinase inhibitors. Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors and others.
On the basis of end users, the eye cancer market is segmented into hospital & clinics, ambulatory care centers and others.
The Americas dominate the eye cancer market owing to the increasing prevalence of people suffering with eye cancer. Additionally, well developed technology, high healthcare expenditure, and strong government support for research & development have fuelled the growth of the Americas eye cancer market. Furthermore, presence of the leading players in this region will support the growth in coming future.
Europe accounts for the second largest eye cancer market, which is followed by Asia Pacific. Strong government support and availability of the funds for research & development have driven the market growth. Asia Pacific is the fastest growing eye cancer market owing to the increasing prevalence of cancer, rapidly developing economy and increasing government support.
On the other hand, the Middle East & Africa hold the least share of the market due to limited availability of funds and availability of medical facilities, and poor political conditions in Africa. The Middle East holds the major share in the Middle East & Africa eye cancer market. Kuwait, Qatar, Oman and South Arabia holds the major share in the Middle East market. However, Africa region is expecting a healthy growth due to presence of huge opportunity for the development of the market.
Sources- WHO, cancer research UK, American Cancer Society
Key Players for Eye Cancer Market
Some of key the players in the eye cancer market are Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (U.S.), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Amgen, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), Sanofi (France), AbbVie Inc. (U.S.), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), Oncomed Pharmaceuticals (U.S.) and Immunomedics (U.S.).
|Market Size||2027: Significant Value|
|CAGR||8.3 % (2017-2023)|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Types, Treatment and End Users|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (U.S.), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Amgen, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), Sanofi (France), AbbVie Inc. (U.S.), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), Oncomed Pharmaceuticals (U.S.) and Immunomedics (U.S.)|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
Eye cancer market is expected to exhibit a CAGR of 8.3% from 2017 to 2023.
Eye cancer market is driven by the high prevalence of intraocular cancer.
High costs of medicines and adverse effects of the treatment can hamper the global eye cancer market growth.
The Americas can be highly lucrative for the global eye cancer market due to prevalence of patients with eye cancer.
Eli Lilly and Company, Janssen Biotech, Inc., Novartis AG, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., AstraZeneca Plc., Amgen, Inc., Spectrum Pharmaceuticals Inc., Oncomed Pharmaceuticals, Pfizer, Inc., Bristol-Myers Squibb Company, Takeda Pharmaceuticals, Immunomedics, AbbVie Inc., GlaxoSmithKline Plc., Bayer AG, and Sanofi are key players of the global eye cancer market.